Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Michelle E Fullard, Sharon X Xie, Ken Marek, Matthew Stern, Danna Jennings, Andrew Siderowf, Allison W Willis, Alice S Chen-Plotkin

Journal: Movement disorders : official journal of the Movement Disorder Society 2018;32(11):1636-1640

PMID: 28906025

Abstract

BACKGROUND

Lower vitamin D levels have been associated with manifest Parkinson's disease, prompting the hypothesis that vitamin D insufficiency or deficiency may increase risk for PD.

OBJECTIVES

To evaluate vitamin D levels in a population at risk for developing PD.

METHODS

Plasma vitamin D levels were measured in the Parkinson Associated Risk Syndrome Study, a cohort of asymptomatic individuals, some of whom are at high risk for PD. Vitamin D levels were compared between subjects at high risk for PD (hyposmia and dopamine transporter scan deficit) versus all others and examined for correlations with dopaminergic system integrity.

RESULTS

Mean vitamin D levels did not differ between groups, with a level of 27.8 ng/mL (standard deviation = 12.0) in the high-risk group versus 24.7 ng/mL (standard deviation = 9.0) in all others (P = 0.09). Vitamin D levels did not associate with putaminal dopamine transporter uptake.

CONCLUSIONS

Our data from the asymptomatic Parkinson Associated Risk Syndrome cohort do not support the hypothesis that chronic vitamin D insufficiency threatens dopaminergic system integrity, contributing to PD pathogenesis. © 2017 International Parkinson and Movement Disorder Society.

© 2017 International Parkinson and Movement Disorder Society.

Address: Parkinson's Disease Research, Education, and Clinical Center (PADRECC), Philadelphia VA Medical Center, Philadelphia, Pennsylvania, USA.; Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA.; Parkinson's Associated Risk Study, New Haven, Connecticut, USA.; Eli Lilly and Company, New York, New York, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.